Phosphorylation Motifs Regulating the Stability and Function of Myocyte Enhancer Factor 2A*

David M. CoxDagger §, Min DuDagger §, Michaela MarbackDagger , Eric C. C. YangDagger §, Joseph ChanDagger , K. W. Michael Siu§, and John C. McDermottDagger ||

From the Dagger  Department of Biology, the § Centre for Research in Mass Spectrometry, and the  Department of Chemistry, York University, Toronto M3J 1P3, Canada

Received for publication, November 5, 2002, and in revised form, February 12, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The phosphorylation status of the myocyte enhancer factor 2 (MEF2) transcriptional regulator is a critical determinant of its tissue-specific functions. However, due to the complexity of its phosphorylation pattern in vivo, a systematic inventory of MEF2A phosphorylation sites in mammalian cells has been difficult to obtain. We employed modern affinity purification techniques, combined with mass spectrometry, to identify several novel MEF2 phosphoacceptor sites. These include an evolutionarily conserved KSP motif, which we show is important in regulating the stability and function of MEF2A. Also, an indirect pathway in which a protein kinase casein kinase 2 phosphoacceptor site is phosphorylated by activation of p38 MAPK signaling was documented. Together, these findings identify several novel aspects of MEF2 regulation that may prove important in the control of gene expression in neuronal and muscle cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Myocyte enhancer factor 2 (MEF2)1 is a transcriptional regulatory complex mediating diverse cellular functions in neurons (1, 2), skeletal (reviewed in Ref. 3) and cardiac muscle (4-6), and T cells (7, 8). It is now well established that MEF2 plays a role in the differentiation of these cell types as well as functioning in a protective role against neuronal apoptosis.

To respond to diverse developmental and physiological cues, MEF2 is structurally organized to receive and respond to multiple signals from several intracellular signaling pathways (reviewed in Refs. 3 and 9). In this regard, perhaps the best characterized is the p38 MAPK-MEF2 axis, in mammals (10, 11) and in yeast (12), although other kinase-catalyzed cascades mediated by big MAP kinase (13, 14), protein kinase C (10), and protein kinase CK2 (15) are known to target MEF2. Moreover, consistent with its role as a signal sensor, putative phosphoacceptor motifs in the carboxyl terminal MEF2 transactivation domain may prove to further modulate MEF2 function in response to extracellular cues.

Given that MEF2, and the biological processes it regulates, are intrinsically governed by MEF2 phosphorylation status, we undertook to systematically document MEF2 phosphorylation patterns in mammalian cells; previous phosphopeptide mapping studies used in vitro phosphorylated MEF2 protein. The purpose thus being to detect physiologically relevant, and possibly novel, in vivo MEF2 phosphorylation sites. To accomplish this we used several state-of-the-art mass spectrometric techniques to detect phosphorylation sites from MEF2 expressed in mammalian cells. To this end, we have made use of a mammalian tandem affinity purification (TAP) method (16, 17) for low-abundance nuclear transcription factors that allows purification to homogeneity and provides amounts compatible with mass spectrometric analysis of phosphorylation sites.

In these studies, we have identified two important and novel aspects of MEF2 regulation. One is a highly conserved phosphoacceptor motif that regulates MEF2 stability and function. The second is an indirect pathway of MEF2 regulation by p38 MAPK mediated by the CK2 holoenzyme. These studies on MEF2 regulation thus identify novel aspects of functional MEF2 regulation that will serve to modulate MEF2 controlled gene expression in a variety of cell types.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Unless otherwise noted, all chemicals were obtained from Sigma-Aldrich. DNA-modifying enzymes were purchased from New England Biolabs (NEB).

Cell Culture and Transfections-- COS7 and HeLa cell cultures were maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing penicillin, streptomycin (Invitrogen), and 10% fetal bovine serum (Atlanta Biologicals). Transfections were performed using the calcium phosphate precipitation method.

His-tagged Protein Purification-- The coding region for human MEF2A was cloned into the EcoRI site of pCDNA 3.1/His (Invitrogen). The coding region for the N-terminal His-MEF2A was then subcloned into the PstI site of pCDNA4/TO/His (Invitrogen). Cells were transfected with 30 µg of DNA per 100-mm dish. Typically, 20 plates of cells were used for a single purification. A standard manufacturer's protocol was used for purification using Ni-Agarose resin (Qiagen).

Tandem Affinity Purification-- The coding region for human MEF2A was ligated into the EcoRI site of pCDNA4/TO/TAP (described in Ref. 17). Cells were transfected with 30 µg of DNA per 100-mm dish. Typically, 5 plates of cells were used for a single purification. The details of mammalian TAP-tagged protein purification are explained in Ref. 17. Briefly, cells were lysed by freeze/thawing. The lysate was passed over IgG resin (Sigma), and the beads were washed. Tagged proteins were eluted by cleaving with TEV protease (Invitrogen) then supplementing with Ca2+ and passed over calmodulin resin (Stratagene) for a second round of purification. Proteins were finally eluted using either 2 mM EGTA or SDS sample buffer and analyzed by SDS-PAGE. Proteins were visualized using Gelcode Blue (Pierce).

In-gel Trypsin Digest-- Protein bands were excised, cut into 1 mm3 pieces, and washed 3 times with 50% acetonitrile/25 mM ammonium bicarbonate for 15 min with shaking. Gel pieces were incubated with 50 mM ammonium bicarbonate + 10 mM dithiothreitol for 30 min at 50 °C, washed with acetonitrile, then incubated with 50 mM ammonium bicarbonate + 55 mM iodoacetamide (freshly made) for 20 min in the dark. The gel pieces were washed with acetonitrile, air dried, and rehydrated with 12.5 ng/µl trypsin (Promega, sequencing grade) in 50 mM ammonium bicarbonate, then incubated at 37 °C overnight. Peptides were extracted once using 3% formic acid, 1 min at 80 °C, followed by 20 min of shaking and 1 min of centrifugation.

Mass Spectrometry-- Peptides were concentrated prior to analysis using µZipTipsTM (Millipore) according to the manufacturer's protocol. Peptides were eluted directly onto a steel target using 10 mg/ml alpha -cyano-4-hydroxycinnamic acid in 65% acetonitrile/0.3% trifluoroacetic acid. To purify phosphopeptides, metal-chelating ZipTipsTM (Millipore) were used with copper(II)-sulfate according to the manufacturer's instructions. Peptide fingerprinting was performed on a Voyager DE-STR (Applied Biosystems) using positive ion reflector mode under optimized conditions. Fragmentation analysis was performed using a nanospray ion source on a prototype Q-Star instrument (Sciex). The instrument was optimized and calibrated daily.

Western Blot Assay-- The MEF2A antibody was generated in rabbits using full-length His-MEF2A purified from bacterial cells. The serum was purified against an immobilized MEF2A column (CnBr-activated agarose, Amersham Biosciences) and IgG was concentrated using a protein A-Sepharose column (Amersham Biosciences). Total protein was separated by 10% SDS-PAGE, transferred (Semi-Dry, Hoefer) to nitrocellulose (Osmonics), blocked with 5% milk in PBS, and probed with alpha -MEF2A overnight. Blots were washed 3 × 10 min with milk in PBS, incubated with secondary (1:10,000, Pierce) for 1 h, then washed 2 × 10 min with milk in PBS + 0.2% Nonidet P-40 and 3 × 10 min in PBS + 0.2% Nonidet P-40. Supersignal West Pico Chemiluminescence (Pierce) was used for detection.

Northern Blot Assay-- Total RNA was isolated with Trizol reagent (Invitrogen) and resolved on a 1% agarose gel in the presence of 6.2% formaldehyde and then blotted on to Nytran membrane (Schleicher & Schuell) in 20× SSC. The complete cDNA (2.9 kb) of MEF2A, excised from pMT2 vector with EcoRI, and a 316-bp glyceraldehyde 3-phosphate dehydrogenase fragment, derived from exons 5-8 (Ambion) and excised with SacI and HindIII, were used as probes for MEF2A and glyceraldehyde 3-phosphate dehydrogenase, respectively. The probes were labeled with 32P using Random Primers DNA Labeling System (Invitrogen) and purified on MicroSpinTM G-25 Columns (Amersham Biosciences). Prehybridization (2 h) and hybridization (overnight) were carried out in 50% deionized formamide, 5× Denhardt's, 5× SSC, 5 mM EDTA, 0.1% SDS, and 200 µg/ml salmon sperm DNA. Membranes were washed and signals were visualized by exposure to film (BioMax MR, Kodak). Between labeling with MEF2A and glyceraldehyde 3-phosphate dehydrogenase, the blots were stripped for 2 h in 50% deionized formamide, 0.1% SSC, 0.1% SDS preheated to 68 °C.

GAL4 Luciferase Assay-- COS7 cells were seeded at 250,000 cells/well in a 6-well dish the day before transfection. Cells were transfected with GAL4 luciferase (0.5 µg), pSV40-beta -galactosidase (0.5 µg), and either GAL4-DBD, GAL4-MEF2A, GAL4-MEF2A (S255D), or GAL4-MEF2A (S255A) (0.3 µg). Cells were fed at 24 h and harvested at 48 h post-transfection in 500 µl of 20 mM Tris, pH 7.4, + 0.1% Triton X-100. 100 µl was used to assay beta -galactosidase activity as an internal control of transfection efficiency. 100 µl of lysate was used to assay luciferase activity (Promega, according to manufacturer's instructions) on a Berthold luminometer (LB9507).

Site-directed Mutagenesis-- The GAL4-MEF2A S255A and S255D mutations were generated using the QuikChange kit (Stratagene) according to the manufacturer's instructions. The primers used were: S255A-GTC ATG CCT ACA AAG GCT CCC CCT CCA CCA G and S255D-GTC ATG CCT ACA AAG GAT CCC CCT CCA CCA G.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression and Purification of MEF2A from Mammalian Cells-- Two purification strategies, His6 and TAP, were employed for obtaining suitable material to probe the phosphorylation status of MEF2A in mammalian cell culture. The His6-MEF2A was expressed in HeLa followed by purification using Ni2+ affinity beads. This strategy was capable of purifying amounts of MEF2A that could be visualized using Coomassie Blue staining (Fig. 1A). More importantly, the purified MEF2A was found in two distinct bands, indicating that a fraction of it had been post-translationally modified. This pattern of mobility is in agreement with previous detection of MEF2A from HeLa (18), COS7, and muscle cell cultures (19) by Western immunoblotting, and is in sharp contrast to the single band obtained when MEF2A is purified from bacterial cells (data not shown). Purified MEF2A protein was subsequently used to characterize its endogenous phosphorylation status.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   Purification of MEF2A from mammalian cell culture. A, His6-tagged MEF2A was overexpressed in HeLa cells and purified using a Ni2+ affinity beads. The proteins were stained by Coomassie Blue and identified by peptide mass fingerprinting. MEF2A was identified in two of the bands, suggesting it had been post-translationally modified. B, TAP-tagged MEF2A, along with p38 MAPK and its upstream activator, MKK6, were overexpressed in COS7 cells. TAP-MEF2A was purified using the TAP scheme (16). The p38 MAPK caused a significant shift in the mobility of MEF2A as detected by Coomassie Blue staining.

To investigate the effect of p38 MAPK on the phosphorylation status of MEF2A, we employed an additional purification strategy utilizing the TAP scheme. TAP-MEF2A was expressed in COS7 cells in the absence or presence of expression vectors for p38 MAPK and a constitutively active upstream regulator, MKK6. The TAP scheme purified MEF2A to near homogeneity, allowing us to use Coomassie Blue staining to reveal the sizable shift in mobility of MEF2A caused by p38 MAPK (Fig. 1B). This shift has previously only been detected by immunoblotting or radiolabelling. This purification was used to probe for novel p38 phosphorylation sites in MEF2A.

Identification of MEF2A-- Proteins were identified by either tryptic mass fingerprinting or CID fragmentation. The MALDI-TOF spectrum for the tryptic digest of MEF2A (Fig. 2A) contains a number of peaks whose masses match the expected mass of peptides from MEF2A. This confidently identifies the protein as MEF2A. Further confirmation was obtained, using a nanospray-QStar instrument, by CID fragmentation of selected peptides. The fragmentation products reveal short sequences and characteristic ions (Fig. 2B) that could only be derived from specific MEF2A peptides. These two types of analyses were subsequently used for identification of phosphopeptides.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Identification of MEF2A and a novel phosphorylation site. A, tryptic peptide mass fingerprint of His6-MEF2A identifies the presence of MEF2A and heat shock cognate 71 kDa. B, the identification of MEF2A was confirmed by sequencing several peptides using CID fragmentation. C, careful inspection of the region around 2000 m/z reveals two peptides separated by 79.94 Da. This suggests that at least a fraction of the peptide is phosphorylated. D, the phosphorylated peptide was confirmed by sequencing using CID fragmentation. The phosphorylated residue is identified as Ser-255.

We used a broad range of techniques to characterize the phosphorylation status of MEF2A in mammalian cell culture. This included comparative analysis between tryptic mass fingerprints, characteristic 80 Da shifts in mass caused by phosphorylation, CID fragmentation, immobilized metal-affinity capture of phosphopeptides, and sequence homology. The details of these analyses will be discussed below.

A Novel, Endogenous Phosphorylation Site in MEF2A-- The MALDI-TOF spectra for tryptic mass fingerprints of MEF2A expressed in mammalian cells were very similar to MEF2A expressed in bacterial cells with one notable exception. A peak at mass 1437.69 Da, corresponding to the amino acids 255-269 (SPPPPGGGNLGMNSR), was significantly lower when MEF2A was expressed and purified from mammalian cells (Fig. 2A), whereas it was prominent in MEF2A expressed in bacterial cells. This prompted us to investigate what was the cause of this difference. A post-translational modification, such as phosphorylation, was a likely candidate; however, no peak was detected at 80, 160, or 240 Da higher in mass. Careful inspection of the region near 2000 m/z (Fig. 2C) revealed a small peak with an m/z value of 1994.02, corresponding to a MEF2A peptide with one missed trypsin cleavage, amino acids 250-269 (VMPTKSPPPPGGGNLGMNSR), and a peak 79.94 Da higher in mass (2073.96). Phosphate incorporation adds 79.97 Da. These data indicate that a measurable fraction of the MEF2A protein pool in mammalian cells is phosphorylated at Ser-255. This sample was then analyzed on a nanospray-QStar instrument to obtain CID fragmentation data (Fig. 2D). Fragmentation of the potential phosphopeptide revealed a clear set of y fragments identifying a stretch of 4 proline residues. Additionally, the fragment at m/z 1419.76 can only be explained by a y15 fragment that has lost H3PO4 (mass loss of 98 Da). These fragments and others confidently identify this peptide as MEF2A 250-269 phosphorylated at Ser-255.

To ascertain the potential importance of this phosphorylation site we compared the sequence of human MEF2A with the other MEF2 family members from various organisms (Fig. 3). The level of sequence homology for this region is remarkable and confirms the high degree of evolutionary conservation of the KSPP phosphorylation motif. The lack of conservation at Thr-253 is in agreement with the fragmentation data, which demonstrates the phosphorylation of Ser-255, not Thr-253.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Sequence comparison between MEF2A Ser-255 region and numerous MEF2 proteins. The sequence KSPPP is conserved across species and MEF2 isoforms. This suggests that phosphorylation of Ser-255 is important for the function of MEF2 proteins.

Phosphorylation of Ser-255 Targets MEF2A for Degradation-- Because Ser-255 is in the MEF2 C-terminal transactivation domain, we assessed the function at this site in a GAL4-based transcriptional response assay by generating mutations of Ser-255 in a GAL4-MEF2A (residues 99-507) fusion protein. These include Ser-255 to aspartic acid (S255D) and Ser-255 to alanine (S255A) mutations. A GAL4 luciferase assay system in COS7 cells was used to determine the activity of these proteins (Fig. 4C). The activity of the S255D mutation was markedly lower than that of either the wild type GAL4-MEF2A or the GAL4-MEF2A (S255A) mutation. A Western blot for MEF2A on cells transfected with these expression vectors indicates decreased full-length protein levels for GAL4-MEF2A (S255D) and evidence of degradation products (Fig. 4B). A Northern blot on these samples demonstrates that transcript expression levels can not account for the differences in GAL4-MEF2A protein levels indicated in Fig. 4B, thus indicating that the decreased protein levels for GAL4-MEF2A (S255D) are likely due to instability of the protein. This is further supported by the detection of at least one large proteolytic fragment by Western analysis (Fig. 4B).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Phosphorylation of Ser-255 targets MEF2A for degradation. COS7 cells were transfected with vectors coding for GAL4 DNA binding domain (Gal4DBD) (lane 1), wild type GAL4DBD-MEF2A (lane 2), or GAL4DBD-MEF2A with serine mutated to either aspartic acid (lane 3) or alanine (lane 4). Cells were harvested, and RNA and protein were isolated. A, Northern blot analysis of total RNA using a MEF2A-specific probe (top row) and glyceraldehyde 3-phosphate dehydrogenase-specific probe (second row). B, Western blot analysis for MEF2A. Proteolytic fragment of GAL4-MEF2A. C, GAL4 luciferase reporter gene assay. Data are expressed relative to the beta -galactosidase corrected luciferase activity for GAL4DBD and are the mean ± S.E. (n = 6).

Identification of Novel p38 MAPK Sites in MEF2A-- Next, we re-visited the p38 MAPK-catalyzed phosphorylation of MEF2A, because p38 MAPK is a potent physiological activator of MEF2 transactivation potential (10, 11). Thr-312 and Thr-319 are known phosphorylation sites important for the increased transcriptional activation of MEF2A by p38 MAPK. Ser-453 and Ser-479 are phosphorylated in vitro but were not important functionally (11). However, previous results indicate that the in vivo phosphorylation of MEF2A by p38 MAPK is possibly more complicated than previously reported (10). A two-dimensional phosphopeptide map of MEF2A expressed in COS7 cells with p38 MAPK and MKK6 showed a very complex pattern of phosphorylation (10) that was different from phosphorylation data derived from in vitro analysis (11). Because this could have important regulatory consequences, we have used mass spectrometry to further dissect and characterize p38 MAPK phosphorylation of MEF2A in mammalian cells.

The tryptic mass fingerprint of MEF2A, co-expressed with p38 MAPK and MKK6, was compared with the lower-mobility band from cells expressing MEF2A alone (Fig. 5). This simple comparison reveals a number of phosphorylated peptides, the evidence for which will now be considered individually.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Mass spectrometry identifies a number of novel p38 MAPK phosphorylation sites in MEF2A. Tryptic peptide maps of MEF2A purified from COS7 cells overexpressing MEF2A alone or with p38 MAPK and MKK6. The p38 MAPK induces the phosphorylation of a number of MEF2A peptides. Potential MAPK phosphoacceptor sites are underlined. Interestingly, peptide (a) does not contain a typical MAPK phosphoacceptor site. This suggests that this site is actually phosphorylated by something downstream of p38 MAPK. b and c contain candidate MAPK sites. d was detected near the limit of detection for this instrument. This region has been magnified and the fourth isotope labeled for clarity.

The peptide of mass 4223.05 (MEF2A 190-233, note that the fourth carbon isotope, 4226.06, is labeled in Fig. 5) has one methionine residue and two potential p38 MAPK phosphorylation sites. Methionine residues are often partially oxidized due to exposure to air. In the p38 MAPK-treated sample there is a peak at a mass 80 Da higher, indicating phosphorylation. This peak is not present in the sample from cells expressing MEF2A alone. Furthermore, the phosphorylated and non-phosphorylated peptides both show evidence of an oxidized form at a mass 16 Da higher from each respective peak. This confirms that this peptide is the phosphorylated form of MEF2A 190-233.

A similar analysis reveals a phosphorylated peptide at mass 2714.32 (MEF2A 475-498). Again, this peptide is 80 Da higher than the non-phosphorylated peptide and is absent from the non-treated sample. Interestingly, in the sample from cells expressing MEF2A alone, the non-phosphorylated peptide is also absent. Occasionally, phosphopeptides lose their phosphate group, either in solution or during ionization. Because this peptide is actually a missed tryptic cleavage of Arg-492, there is the possibility that phosphorylation of this peptide interfered with the trypsin digestion, prior to the loss of phosphate.

The MEF2A 95-114 peptide has a mass of 2247.99 whereas its phosphorylated form is found at 2327.96. The intensity of the latter peak is quite high compared with the former peak. However, it is difficult to quantify these peptides based on peak intensity, as the energy required to ionize a phosphopeptide may differ from its non-phosphorylated form.

In addition to peptide mass fingerprinting, we employed CID fragmentation to sequence putative phosphopeptides. Furthermore, the efficiency of nanospray ionization employed in this instrument differs from that of the MALDI source used for peptide mass fingerprinting. This form of ionization was particularly suitable for detecting the MEF2A phosphopeptide 404-413 (doubly charged m/z of 617.28). Subsequent CID fragmentation of this peptide confirmed the presence of phosphorylation (loss of H3PO4 from the precursor ion and several fragment ions) at Ser-408 (Fig. 6).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   An additional MEF2A phosphopeptide identified by CID fragmentation. The doubly charged precursor of m/z 617.28 was identified as phosphorylated MEF2A (404-413). Phosphorylation is confirmed by the loss of H3PO4 from the doubly charged precursor. The phosphorylation site is identified as Ser-408 by the loss of H3PO4 from y6 and y8 fragments and from the internal fragment (IpSP).

A p38 MAPK-induced Phosphopeptide with no MAPK Consensus-- Of particular interest is the MEF2A peptide 283-300. This region of MEF2A is alternatively spliced, and this particular splice variant is abundant in muscle and nerve cells. Phosphorylation of this peptide is indicated by the 80 Da shift in mass to 2182.95; however, this peptide does not contain a proline-directed MAPK consensus site (Fig. 7A). Further evidence that this peptide is phosphorylated is provided by the oxidation of the two methionine residues in this peptide. The phosphorylated peptide shows evidence of two oxidized methionine residues, in agreement with the two oxidized methionine residues seen for the non-phosphorylated peptide. Additional evidence that at least a fraction of this peptide is phosphorylated is provided by the use of a copper immobilized metal-affinity capture purification. MEF2A tryptic peptides were fractionated using a copper(II)-sulfate-treated metal chelating ZipTipTM. Phosphorylated peptides have a higher affinity for Cu2+ than non-phosphorylated peptides. The selectively bound peptides were eluted, concentrated on a C-18 ZipTipTM, and analyzed by MALDI-TOF. The presence of the m/z 2182.92 peptide in this eluate confirms the phosphorylation status of the MEF2A 283-300 peptide (Fig. 7B). Sequence analysis of this peptide reveals a strong consensus motif that is targeted by protein kinase CK2. Because phosphorylation of this peptide is dependent on p38 MAPK activation, cross-talk between p38 and protein kinase CK2 in MEF2A phosphorylation is implicated by these data (see "Discussion").


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Evidence for p38 MAPK-induced phosphorylation of MEF2A 283-300. A, the MEF2A 283-300 peptide contains two methionine residues that are often oxidized upon exposure to air. The peptide at m/z 2182.95 also shows evidence of oxidation. This supports the idea that 2182.95 is the phosphorylated form of MEF2A 283-300. B, immobilized Cu2+ affinity ZipTipsTM were used to purify tryptic phosphopeptides from MEF2A. The m/z 2182.92 adds further proof that MEF2A 283-300 is phosphorylated in cells overexpressing p38 MAPK. The m/z 2102.97 peptide is likely a result of gas-phase dephosphorylation of the m/z 2182.92 peptide.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In these studies we have used state-of-the-art mass spectrometric techniques to asses the in vivo phosphorylation pattern of the MEF2A transcriptional regulator. This approach has yielded novel information concerning the regulation of MEF2: first, the identification of a novel phosphoacceptor site that regulates MEF2 stability; second, the identification of previously uncharacterized p38 MAPK phosphoacceptor sites; and third, the discovery of a protein kinase CK2 consensus phosphoacceptor site that requires p38 MAPK activity to be phosphorylated. These studies constitute several novel aspects of MEF2 regulation by reversible phosphorylation.

Phosphorylation of Ser-255 in MEF2A by endogenous kinases is detected in several cell types (C2C12, COS, and HeLa), and this phosphorylation is independent of the activity of p38 MAPK (Fig. 5). This sequence is highly conserved in members of the MEF2 family across numerous species, highlighting the importance of this site in the regulation of MEF2 proteins. The conserved sequence consists of a KSP motif, which is a known phosphoacceptor site for several kinases. This includes MAPK members (ERK1, ERK2, and stress-activated protein kinase) (20, 21), cdc2-like kinases (including CDK5) (22, 23), and glycogen synthase kinase 3 (24). The presence of these proteins in both muscle and nerve cells is suggestive of a link between these pathways and the functional consequences of phosphorylation of this site in MEF2.

The extracellular-regulated kinases (ERK1 and ERK2) are abundant in nerve cells (25) and have been implicated in the myogenic program (26-30). The activity of ERK is biphasic, with higher activity in myoblasts and later stage myotubes (26, 28). In the early stages of the myogenic program, ERK has an inhibitory effect on the expression of myogenic regulators and muscle-specific proteins (28, 29). In later stages of differentiation, ERK appears to enhance the formation of mature myotubes (26, 27) and induce hypertrophy (30). Thus, phosphorylation-induced degradation of MEF2 proteins by ERK would explain the early inhibitory effect that ERK has on the myogenic program.

The CDK5 protein is found predominantly in nervous tissue, although it has also been detected in muscle and other non-neural tissues. It has been implicated in migration, actin dynamics, microtubule transport, cell adhesion, axon guidance, synaptic structure and plasticity, membrane transport, and myogenesis (31). In muscle cells CDK5 can be detected throughout the myogenic program. The level of expression and activity of CDK5 is increased during myogenesis. In addition, proliferating myoblasts show a predominantly cytoplasmic localization of CDK5, whereas differentiating cells have an increase in nuclear levels of CDK5 (32). The possibility exists that CDK5 has a role in regulating the activity of MEF2 proteins by direct phosphorylation, although how this would pertain to regulation of MEF2 by degradation would require further investigation.

The ubiquitous phosphorylation of Ser-255, coupled with its role in the degradation of MEF2, points tantalizingly toward a role for glycogen synthase kinase 3. Originally thought of as an enzyme solely involved in glycogen metabolism, this ubiquitous kinase is now known to be involved in numerous cellular signaling functions (33). Overexpression of active glycogen synthase kinase 3 induces apoptosis in neuronal cells by phosphorylation of downstream targets (34). In addition, glycogen synthase kinase 3 is known to phosphorylate several proteins, which are subsequently targeted for degradation (35, 36). It is interesting to note that MEF2 has recently been identified as protecting neuronal cells from apoptosis (2, 37, 38) and that it is also targeted for degradation by phosphorylation (39). Whether Ser-255 is the targeted residue that links MEF2 degradation and neuronal apoptosis will be of great interest.

MEF2A has been convincingly identified as a target for p38 MAPK. Phosphorylation of MEF2A by p38 MAPK strongly increases the transcriptional activity of MEF2A, and this increase in activity has been mapped to a couple of key residues (Thr-312 and Thr-319) (10, 11). However, in vivo phosphorylation of MEF2A by p38 MAPK produces a complex pattern of phosphorylation that cannot be entirely explained by these two key residues. The possibility, therefore, remains that other sites within MEF2A are involved in p38 MAPK signaling. Although the tryptic phosphopeptide containing Thr-312 and Thr-319 was too large to detect by mass spectrometry, the data from this study conclusively identify several new phosphorylation sites, induced by p38 MAPK activity (Fig. 8).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Summary of phosphorylation sites in MEF2A. A number of phosphorylation sites have been identified here or in previous reports (11, 15). These sites and their likely kinase are indicated. Important features, such as alternative splicing (87-132 and 288-295) and the p38 docking site, are also indicated.

Most notable among these p38 MAPK-induced phosphorylation sites is the confirmation of phosphorylation at a consensus protein kinase CK2 site, Ser-289. This region of MEF2A (and the homologous region of MEF2C) is known to be alternatively spliced in different tissues (40, 41), suggesting a possible tissue-specific functional role for this region. Its sequence is highly suggestive of a protein kinase CK2 site ((S/T)XX(D/E)) that, until now, had not been confirmed as a phosphoacceptor site. The data presented here demonstrates that Ser-289 is likely a target of protein kinase CK2, but more interestingly, it suggests a link between p38 MAPK activity and the phosphorylation of MEF2A by protein kinase CK2. In fact, a previous report indicates that the CK2 holoenzyme (alpha  and beta  subunits) can be activated specifically by p38 MAPK (42), indicating the possibility that CK2 and p38 MAPK may cooperatively dock with MEF2A.

MEF2 proteins are involved in a number of different cellular processes including proliferation, differentiation, apoptosis, and hypertrophy. These disparate roles for MEF2 are partly explained by the regulated activation of specific signaling pathways. Here we provide conclusive evidence for the phosphorylation of MEF2A by a number of signal-dependant kinases. These data concerning reversible phosphorylation of MEF2A will be a fundamental aspect of understanding the diverse function of MEF2 proteins.

    ACKNOWLEDGEMENT

We thank Dr. Séraphin for providing us with the yeast TAP-tag vectors.

    FOOTNOTES

* This study was supported by grants from the Canadian Institutes of Health Research (CIHR), Natural Science and Engineering Research Council (NSERC), Heart and Stroke Foundation of Canada, MDS Sciex, and York University. Some hardware funding was provided by the Canada Foundation for Innovation (CFI) and the Ontario Innovation Trust (OIT).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: York University, 4700 Keele St., 247 Farquharson Bldg., Toronto M3J 1P3, Canada. Tel.: 416-736-2100 (ext. 30389); Fax: 416-736-5698; E-mail: jmcderm@yorku.ca.

Published, JBC Papers in Press, February 12, 2003, DOI 10.1074/jbc.M211312200

    ABBREVIATIONS

The abbreviations used are: MEF2, myocyte enhancer factor 2; TAP, tandem affinity purification; MAPK, mitogen-activated protein kinase; MALDI, matrix-assisted laser desorption ionization; TOF, time of flight; ERK, extracellular-regulated kinases; CK2, casein kinase 2; DBD, DNA binding domain; MKK6, MAP kinase kinase; CID, collision-induced dissociation; CDK5, cyclin-dependent kinase 5.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Lin, X., Shah, S., and Bulleit, R. F. (1996) Brain Res. Mol. Brain Res. 42, 307-316[CrossRef][Medline] [Order article via Infotrieve]
2. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M., and Greenberg, M. E. (1999) Science 286, 785-790[Abstract/Free Full Text]
3. Naya, F. S., and Olson, E. (1999) Curr. Opin. Cell Biol. 11, 683-688[CrossRef][Medline] [Order article via Infotrieve]
4. Edmondson, D. G., Lyons, G. E., Martin, J. F., and Olson, E. N. (1994) Development 120, 1251-1263[Abstract/Free Full Text]
5. Lin, Q., Schwarz, J., Bucana, C., and Olson, E. N. (1997) Science 276, 1404-1407[Abstract/Free Full Text]
6. Han, J., and Molkentin, J. D. (2000) Trends Cardiovasc. Med. 10, 19-22[CrossRef][Medline] [Order article via Infotrieve]
7. Youn, H. D., Sun, L., Prywes, R., and Liu, J. O. (1999) Science 286, 790-793[Abstract/Free Full Text]
8. Swanson, B. J., Jack, H. M., and Lyons, G. E. (1998) Mol. Immunol. 35, 445-458[CrossRef][Medline] [Order article via Infotrieve]
9. Cox, D. M., Quinn, Z. A., and McDermott, J. C. (2000) Exerc. Sport Sci. Rev. 28, 33-38[Medline] [Order article via Infotrieve]
10. Ornatsky, O. I., Cox, D. M., Tangirala, P., Andreucci, J. J., Quinn, Z. A., Wrana, J. L., Prywes, R., Yu, Y. T., and McDermott, J. C. (1999) Nucleic Acids Res. 27, 2646-2654[Abstract/Free Full Text]
11. Zhao, M., New, L., Kravchenko, V. V., Kato, Y., Gram, H., di Padova, F., Olson, E. N., Ulevitch, R. J., and Han, J. (1999) Mol. Cell. Biol. 19, 21-30[Abstract/Free Full Text]
12. Dodou, E., and Treisman, R. (1997) Mol. Cell. Biol. 17, 1848-1859[Abstract]
13. Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., and Lee, J. D. (1997) EMBO J. 16, 7054-7066[Abstract/Free Full Text]
14. Yang, C. C., Ornatsky, O. I., McDermott, J. C., Cruz, T. F., and Prody, C. A. (1998) Nucleic Acids Res. 26, 4771-4777[Abstract/Free Full Text]
15. Molkentin, J. D., Li, L., and Olson, E. N. (1996) J. Biol. Chem. 271, 17199-17204[Abstract/Free Full Text]
16. Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., and Seraphin, B. (1999) Nat. Biotechnol. 17, 1030-1032[CrossRef][Medline] [Order article via Infotrieve]
17. Cox, D. M., Du, M., Guo, X., Siu, K. W. Michael, and McDermott, J. C. (2002) BioTechniques 33, 267-270[Medline] [Order article via Infotrieve]
18. Lemercier, C., Verdel, A., Galloo, B., Curtet, S., Brocard, M. P., and Khochbin, S. (2000) J. Biol. Chem. 275, 15594-15599[Abstract/Free Full Text]
19. Quinn, Z. A., Yang, C. C., Wrana, J. L., and McDermott, J. C. (2001) Nucleic Acids Res. 29, 732-742[Abstract/Free Full Text]
20. Veeranna, Amin, N. D., Ahn, N. G., Jaffe, H., Winters, C. A., Grant, P., and Pant, H. C. (1998) J. Neurosci. 18, 4008-4021[Abstract/Free Full Text]
21. Giasson, B. I., and Mushynski, W. E. (1997) J. Neurosci. 17, 9466-9472[Abstract/Free Full Text]
22. Shetty, K. T., Link, W. T., and Pant, H. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6844-6848[Abstract]
23. Lew, J., and Wang, J. H. (1995) Trends Biochem. Sci. 20, 33-37[CrossRef][Medline] [Order article via Infotrieve]
24. Guan, R. J., Khatra, B. S., and Cohlberg, J. A. (1991) J. Biol. Chem. 266, 8262-8267[Abstract/Free Full Text]
25. Fukunaga, K., and Miyamoto, E. (1998) Mol. Neurobiol. 16, 79-95[Medline] [Order article via Infotrieve]
26. Wu, Z., Woodring, P. J., Bhakta, K. S., Tamura, K., Wen, F., Feramisco, J. R., Karin, M., Wang, J. Y., and Puri, P. L. (2000) Mol. Cell. Biol. 20, 3951-3964[Abstract/Free Full Text]
27. Gredinger, E., Gerber, A. N., Tamir, Y., Tapscott, S. J., and Bengal, E. (1998) J. Biol. Chem. 273, 10436-10444[Abstract/Free Full Text]
28. Bennett, A. M., and Tonks, N. K. (1997) Science 278, 1288-1291[Abstract/Free Full Text]
29. Coolican, S. A., Samuel, D. S., Ewton, D. Z., McWade, F. J., and Florini, J. R. (1997) J. Biol. Chem. 272, 6653-6662[Abstract/Free Full Text]
30. Musaro, A., McCullagh, K. J., Naya, F. J., Olson, E. N., and Rosenthal, N. (1999) Nature 400, 581-585[CrossRef][Medline] [Order article via Infotrieve]
31. Dhavan, R., and Tsai, L. H. (2001) Nat. Rev. Mol. Cell. Biol. 2, 749-759[CrossRef][Medline] [Order article via Infotrieve]
32. Lazaro, J. B., Kitzmann, M., Poul, M. A., Vandromme, M., Lamb, N. J., and Fernandez, A. (1997) J. Cell Sci. 110, 1251-1260[Abstract/Free Full Text]
33. Cohen, P., and Frame, S. (2001) Nat. Rev. Mol. Cell. Biol. 2, 769-776[CrossRef][Medline] [Order article via Infotrieve]
34. Pap, M., and Cooper, G. M. (1998) J. Biol. Chem. 273, 19929-19932[Abstract/Free Full Text]
35. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J. R. (2000) Genes Dev. 14, 2501-2514[Abstract/Free Full Text]
36. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. (1998) Genes Dev. 12, 3499-3511[Abstract/Free Full Text]
37. Okamoto, S., Li, Z., Ju, C., Scholzke, M. N., Mathews, E., Cui, J., Salvesen, G. S., Bossy-Wetzel, E., and Lipton, S. A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 3974-3979[Abstract/Free Full Text]
38. Okamoto, S., Krainc, D., Sherman, K., and Lipton, S. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7561-7566[Abstract/Free Full Text]
39. Li, M., Linseman, D. A., Allen, M. P., Meintzer, M. K., Wang, X., Laessig, T., Wierman, M. E., and Heidenreich, K. A. (2001) J. Neurosci. 21, 6544-6552[Abstract/Free Full Text]
40. McDermott, J. C., Cardoso, M. C., Yu, Y. T., Andres, V., Leifer, D., Krainc, D., Lipton, S. A., and Nadal-Ginard, B. (1993) Mol. Cell. Biol. 13, 2564-2577[Abstract]
41. Yu, Y. T., Breitbart, R. E., Smoot, L. B., Lee, Y., Mahdavi, V., and Nadal-Ginard, B. (1992) Genes Dev. 6, 1783-1798[Abstract]
42. Sayed, M., Kim, S. O., Salh, B. S., Issinger, O. G., and Pelech, S. L. (2000) J. Biol. Chem. 275, 16569-16573[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.